Table 3.
Prognostic significance of circulating tumor cells for overall survival subdivided by subtype of primary tumor
| Subtype of primary tumor | Overall survival in months <5 CTCs |
Overall survival in months ≥5 CTCs |
P value |
|---|---|---|---|
| Luminala | 21.2 (16.5-26.5) | 7.4 (4.8-10.1) | 0.003 |
| HER2 subtype | 25.2 (18.3-32.1) | 12.1 (7.9-16.2) | 0.027 |
| Triple-negative | 26.7 (22.6-30.9) | 19.7 (16.2-23.1) | 0.003 |
Values of overall survival are presented as mean (95% confidence interval). aHormone receptor-positive and HER2-negative. CTC, circulating tumor cell; HER2, human epidermal growth factor receptor 2.